D
uring the course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a transition to an aggressive large cell lymphoma may occur. Th is is referred to as Richter's syndrome and occurs in about 5% of cases of CLL/SLL (1, 2) . Transformation to Hodgkin lymphoma has infrequently been described as the "Hodgkin variant of Richter transformation." It might be more appropriately termed Hodgkin transformation of CLL/SLL. We report a man with chronic lymphocytic leukemia who developed Hodgkin lymphoma during the course and treatment of his primary disease and review previously published reports of this transformation.
CASE REPORT
A 44-year-old man was well until September 2011, when he presented with massive lymphadenopathy and a white cell count of over 300 K/μL (Figure 1) . He was subsequently diagnosed with CLL/SLL by morphology and fl ow cytometry. He underwent plasmapheresis and was started on rituximab and bendamustine. He showed a good response to chemotherapy and by February 2012 had only minimal residual disease. He completed eight cycles of chemotherapy up to May 2012. He then started having watery diarrhea and became febrile (up to 105°F). He was admitted to Baylor Regional Medical Center at Grapevine in May 2012 for evaluation and treatment of his symptoms. Blood cultures were negative. His stool culture was positive for Giardia lamblia. He was then treated with metronidazole, nitazoxanide, and octreotide with control of the diarrhea. However, he remained febrile. An abdominal computed axial tomography study showed hepatosplenomegaly and mild lymphadenopathy. A complete blood count revealed pancytopenia. Additionally, his lactate dehydrogenase level was normal. A bone marrow biopsy showed two small focal areas containing atypical cells suspicious for involvement by Hodgkin lymphoma. Th ere was no evidence of residual CLL/SLL. To establish a defi nitive diagnosis, an additional bone marrow biopsy was performed a week later and showed several atypical cellular areas containing Reed-Sternberg-like cells (Figure 2 ). Immunohistochemical stains revealed the large cells to be positive for CD30 and CD15 (Figure 3 ) and negative for Oct2 and Bob.1. An in situ stain for Epstein-Barr virus was also positive in these cells (Figure 4 ). Th ese fi ndings supported the diagnosis of Hodgkin lymphoma. Th ere was no morphologic or (6, 11) . In the type 2 transformation, H-RS cells are present in a typical polymorphous, infl ammatory background separate from CLL cells (9-11). Our case fi ts the type 2 pattern. In the type 1 transformation, histologic and immunophenotypic fi ndings suggest that the H-RS cells represent histologic progression of the underlying CLL cells, especially when the H-RS cells express B cell markers (12) . Although in the type 2 transformation, two diff erent disease types are considered to be present, the two lesions may be related. It is unknown whether the two types of Hodgkin transformation in CLL/SLL are associated with distinct clinical and prognostic features. Th e H-RS cells and the CLL cells seem to have a clonal relationship using single-cell polymerase chain reaction analysis and DNA sequencing (12) .
In the M. D. Anderson series, the median overall survival was 0.8 years (range 0.03-6.7+). Th e median failure-free survival duration was 0.4 years. Fourteen of the 18 patients were treated with chemotherapy. Nine patients received Hodgkin lymphoma-type therapy, including fi ve patients who received ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), three patients who received CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone), and one patient who received CVPP/ABVD. Five other patients received other cytotoxic regimens with or without rituximab. All patients died from disease recurrence or progressive disease without responding to therapy. Most of the other papers report an equally poor response. Although the number of patients in the M. D. Anderson series was small (although it is still the largest series reported), the authors suggested that newer, more eff ective intensifi ed combined-modality regimens may be more eff ective. 
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One paper reported a partially successful treatment (5). Th is patient was treated with lomustine, mitoxantrone, and vinblastine and achieved a complete response but relapsed and died 2 years and 2 months after the diagnosis of Hodgkin disease. Another short correspondence from 2000 described three cases of patients with CLL who subsequently developed Hodgkin disease and had a good response with complete remission (13) . Two patients were treated with intensive chemotherapy (Stanford V regimen) followed by radiotherapy, and one patient received three courses of MOPP (mechlorethamine, vincristine, procarbazine, prednisone)/ABVD (14) . Th e authors also stated that such an outcome was rare. One piece of information that is not consistently available in the papers is the stage of Hodgkin lymphoma at the time of diagnosis, which may have some infl uence on the outcome. Our case was stage IV. An association with Epstein-Barr virus (also present in our case) has been noted; it is important to determine whether this virus is present and, if so, antiviral therapy might be incorporated in combination with chemotherapy (6, 14) .
Although Hodgkin lymphoma transformation is infrequent in CLL/SLL, the prognosis is unfavorable. It will be important to evaluate any newer innovative regimens developed for Hodgkin lymphoma.
